BA
IONS icon

Bridgewater Associates’s Ionis Pharmaceuticals IONS Stock Holding History

Bridgewater Associates’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-67,706
Closed -$5.36M – 1122
2025
Q4 		$5.36M Buy
67,706
+24,128
+55% +$1.82M 0.02% 509
2025
Q3 		$2.85M Buy
+43,578
New +$2.13M 0.01% 639
2022
Q3 		– Sell
-9,779
Closed -$362K – 936
2022
Q2 		$362K Buy
9,779
+2,578
+36% +$97.2K ﹤0.01% 926
2022
Q1 		$267K Buy
+7,201
New +$236K ﹤0.01% 944
2021
Q3 		– Sell
-7,981
Closed -$318K – 740
2021
Q2 		$318K Buy
+7,981
New +$313K ﹤0.01% 679

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bridgewater Associates's IONS Position: Q1 2026 in Review

Bridgewater Associates sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 67,706 shares — an estimated $5.36M sold.

Bridgewater Associates first reported a position in IONS in Q2 2021 and held it in 5 quarters. The position peaked at $5.36M in Q4 2025. 496 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Bridgewater Associates reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bridgewater Associates sold 67,706 Ionis Pharmaceuticals shares in Q1 2026, an estimated $5.36M.
  • Bridgewater Associates first reported a position in Ionis Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Bridgewater Associates's Ionis Pharmaceuticals position peaked at $5.36M in Q4 2025.
  • 496 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.